-
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
Latest News
-
Gene therapy meets stem cells in liver disease success
Scientists combine gene therapy and stem cells to correct a genetic liver disease. Could this combo be retooled for H
-
Chinese Huntington’s Disease Network launched
Chinese Huntington’s Disease Network launched. Good news for China, good news for the global HD community
-
HDAC inhibitor drug protects memory in HD mice
CBP, a gene-switching protein, protects memory in HD mice; 'histone deacetylase inhibitor' drug mimics its effects
-
Turning down the volume with dantrolene helps HD mice
Dantrolene, an muscle-relaxer drug already on the market, helps HD mice by reducing cellular calcium levels
-
TRACK-HD reveals changes in HD mutation carriers, empowering future trials
Follow-up data from TRACK-HD study proves that we have the tests we need to successfully run drug trials for HD
-
Huntexil hits the headlines again
Huntexil makes headlines with science journal article, but nothing's changed: another trial is needed before approval
-
New antibody reveals dangerous parts of huntingtin protein
A new antibody lets scientists identify neurons that are going to die after producing mutant huntingtin
-
Safety trials add crucial piece to gene silencing jigsaw
Three trials of drugs to 'silence' the HD gene in monkeys show they hit the target safely. Human trials coming soon.
-
Melatonin treatment success in HD mice
Melatonin delays disease onset and extends survival in Huntington's disease mice – could it do the same for patients?
-
HD World Congress 2011: a retrospective
HDBuzz looks back at the highlights of the Huntington's disease world congress 2011 in Melbourne
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
